Transcranial Magnetic Stimulation (TMS): How It Works, What It Treats, and What to Expect

Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses magnetic fields to modulate neural activity in targeted regions of the brain. Unlike electroconvulsive therapy (ECT), TMS does not require anesthesia, does not induce seizures, and is performed on an outpatient basis. The procedure was first approved by the U.S. Food and Drug Administration (FDA) in 2008 for the treatment of major depressive disorder in adults who had not responded adequately to at least one antidepressant medication.

TMS works by delivering focused magnetic pulses through a coil placed against the scalp. These pulses generate small electrical currents in the underlying brain tissue, which can either excite or inhibit neural circuits depending on the stimulation parameters. The most common target is the left dorsolateral prefrontal cortex (DLPFC), a brain region involved in mood regulation, executive function, and emotional processing. In individuals with treatment-resistant depression, this area often shows reduced activity — and TMS aims to restore more typical patterns of neural firing.

It is important to understand that TMS is a neuromodulation technique — it changes how brain circuits function rather than introducing a chemical substance into the body. This distinguishes it from pharmacological treatments and places it in the same broad category as other brain stimulation approaches, including ECT, vagus nerve stimulation (VNS), and deep brain stimulation (DBS), though TMS is significantly less invasive than any of these alternatives.

The physics behind TMS are rooted in electromagnetic induction — the same principle that powers electric motors and transformers. A coil of wire carrying a rapidly changing electrical current generates a magnetic field that passes through the skull and induces a secondary electrical current in cortical neurons. This current is strong enough to depolarize neurons (trigger them to fire) but weak enough to remain focused on a specific brain region.

There are several forms of TMS used in clinical practice:

• Repetitive TMS (rTMS): The most widely used clinical form. It delivers repeated pulses at a set frequency. High-frequency stimulation (typically 10 Hz) applied to the left DLPFC is thought to increase cortical excitability and has antidepressant effects. Low-frequency stimulation (1 Hz) applied to the right DLPFC can decrease excitability and is sometimes used as an alternative protocol.
• Deep TMS (dTMS): Uses an H-coil design that can reach deeper brain structures (approximately 4–6 cm below the scalp, compared to 1.5–2 cm for standard figure-eight coils). Deep TMS received FDA clearance for depression in 2013 and for obsessive-compulsive disorder (OCD) in 2018.
• Theta Burst Stimulation (TBS): A newer protocol that delivers bursts of stimulation mimicking natural theta rhythms in the brain. Intermittent theta burst stimulation (iTBS) can achieve comparable results to traditional rTMS in a fraction of the time — sessions last approximately 3 minutes rather than 37 minutes. The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, which uses iTBS delivered multiple times per day over five days, has shown particularly promising results in research settings.

The therapeutic effects of TMS are believed to depend on neuroplasticity — the brain's ability to reorganize its connections and patterns of activity. Repeated stimulation sessions are thought to strengthen synaptic connections in underactive circuits (a process called long-term potentiation) or weaken overactive circuits (long-term depression), gradually shifting brain activity toward healthier patterns. This is why a full course of treatment requires multiple sessions over several weeks rather than producing instant results.

TMS has the strongest evidence base and most established clinical use in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression — defined as depression that has not responded to at least one adequate trial of antidepressant medication. This remains the primary FDA-cleared indication for TMS.

Beyond depression, TMS has received FDA clearance for several additional conditions:

• Obsessive-Compulsive Disorder (OCD): Deep TMS targeting the anterior cingulate cortex and medial prefrontal cortex received FDA clearance in 2018 for adults with OCD who have not responded to conventional treatments.
• Smoking Cessation: Deep TMS was cleared by the FDA in 2020 as a short-term aid for smoking cessation, targeting brain regions involved in addiction and craving.
• Anxious Depression: In 2021, the FDA cleared TMS specifically for MDD with comorbid anxiety symptoms, acknowledging that this common presentation responds to brain stimulation approaches.
• Migraine: Single-pulse TMS devices have received FDA clearance for the acute treatment of migraine with aura, though this is a neurological rather than psychiatric application.

Researchers are actively investigating TMS for a range of other conditions, including post-traumatic stress disorder (PTSD), generalized anxiety disorder, bipolar depression, substance use disorders, eating disorders, and chronic pain syndromes. While some of this research is promising, these remain off-label uses, meaning the evidence is not yet sufficient for formal FDA clearance. Clinicians may still offer TMS for these conditions based on emerging data, but patients should be informed of the investigational nature of such use.

It is also worth noting that TMS is not a first-line treatment for any condition. Clinical guidelines consistently recommend it for individuals who have not achieved adequate improvement with standard interventions such as psychotherapy and medication.

Understanding what happens before, during, and after TMS sessions can help reduce anxiety about the procedure and set realistic expectations.

Before Treatment — Evaluation and Mapping

Before starting TMS, a clinician will conduct a thorough psychiatric evaluation to determine whether TMS is appropriate. This includes reviewing diagnosis, medication history, treatment response, and any contraindications. At the first session, the TMS technician will perform motor threshold mapping — placing the coil over the motor cortex and gradually increasing the pulse intensity until it causes a visible twitch in the hand. This measurement determines the minimum stimulation intensity needed to activate neurons, and the treatment dose is set as a percentage of this threshold (typically 120% for standard rTMS). The treatment coil is then repositioned to target the DLPFC based on standardized measurements from the motor cortex location, or in some clinics, guided by neuroimaging.

During a Session

Patients sit in a reclined chair, awake and alert, with no sedation required. The TMS coil is placed against the scalp, and patients hear a clicking or tapping sound as the magnetic pulses are delivered. Most people describe the sensation as a tapping or light knocking on the head. Some individuals find it mildly uncomfortable initially, particularly around the temples, but most report that the sensation becomes easier to tolerate over subsequent sessions.

• Standard rTMS sessions: Approximately 20–40 minutes
• Theta burst stimulation (iTBS) sessions: Approximately 3–10 minutes
• Full treatment course: Typically 30–36 sessions delivered 5 days per week over 6–9 weeks for standard protocols

Patients can drive themselves to and from treatment and return to normal activities immediately afterward. There is no recovery period required.

After the Treatment Course

Improvement is usually gradual rather than sudden. Many patients begin to notice changes in mood, energy, sleep, or motivation after 2–4 weeks of treatment, with continued improvement through the end of the course and sometimes in the weeks following completion. Some patients undergo maintenance or taper sessions — less frequent stimulation sessions designed to sustain the therapeutic benefit over time. Relapse is possible, and some individuals may benefit from repeat courses of treatment.

The evidence supporting TMS for treatment-resistant depression is substantial and continues to grow. Multiple large-scale randomized controlled trials and meta-analyses have demonstrated that TMS is significantly more effective than sham (placebo) stimulation.

Key findings from the clinical literature include:

• Response rates (clinically meaningful improvement, typically defined as a 50% or greater reduction in depression severity scores) range from approximately 40–60% in most clinical trials and real-world outcome data.
• Remission rates (near-complete resolution of depressive symptoms) range from approximately 25–35% in controlled trials, though real-world clinical data sometimes report higher rates.
• A landmark 2010 randomized controlled trial published in Biological Psychiatry (the OPT-TMS study) demonstrated statistically significant superiority of active TMS over sham stimulation for treatment-resistant depression, with a remission rate of approximately 14% for active TMS versus 5% for sham in a rigorously controlled design.
• Real-world effectiveness data from large clinical registries, including a major study published in the Journal of Clinical Psychiatry in 2018, have reported response rates of approximately 58% and remission rates of approximately 37% in over 5,000 patients — higher than controlled trials, likely because clinicians can optimize treatment parameters for individual patients.
• The SAINT protocol (Stanford Accelerated Intelligent Neuromodulation Therapy), an accelerated iTBS protocol guided by functional neuroimaging, produced remission rates of approximately 79% in a small but rigorous double-blind trial published in the American Journal of Psychiatry in 2022. These results are unprecedented but require replication in larger samples.

For OCD, evidence is more limited but growing. A pivotal trial published in the American Journal of Psychiatry in 2019 demonstrated a significant benefit of deep TMS over sham stimulation, with a response rate of approximately 38% versus 11% for sham.

Important context: TMS is studied primarily in individuals who have already failed other treatments. The comparison is not "TMS versus antidepressants in treatment-naïve patients" — it is "TMS versus continued treatment-as-usual in people who are already difficult to treat." In that context, the response and remission rates are clinically meaningful.

Evidence for TMS in conditions beyond depression and OCD is generally considered emerging. Several randomized controlled trials support its use in PTSD, and initial studies in substance use disorders and other conditions are promising but not yet definitive.

One of the most significant advantages of TMS is its favorable side effect profile compared to both medications and other brain stimulation techniques. TMS does not cause the weight gain, sexual dysfunction, sedation, or cognitive impairment commonly associated with antidepressant medications. It does not require anesthesia and does not cause the memory loss associated with ECT.

Common side effects include:

• Scalp discomfort or pain at the stimulation site: This is the most frequently reported side effect, occurring in approximately 20–40% of patients. It is usually mild, tends to decrease with repeated sessions, and can be managed with over-the-counter analgesics.
• Headache: Mild to moderate headaches after sessions occur in roughly 20–30% of patients and typically respond to standard pain relievers.
• Lightheadedness: A small percentage of patients report transient dizziness or lightheadedness during or after stimulation.
• Facial twitching: Involuntary contraction of scalp or facial muscles during stimulation is common and harmless.

Rare but serious risks:

• Seizure: This is the most serious potential adverse event. The risk is extremely low — estimated at less than 0.1% (roughly 1 in 10,000 sessions or fewer) when safety guidelines are followed. Established protocols include specific limits on stimulation frequency, intensity, and duration that are designed to minimize seizure risk.
• Hearing changes: The device produces loud clicking sounds. Earplugs are provided during treatment and should always be worn to prevent any risk of hearing damage.

Absolute contraindications include:

• Ferromagnetic metallic implants in or near the head (excluding standard dental fillings), such as cochlear implants, metallic clips from aneurysm repair, or embedded shrapnel
• Implanted stimulators (e.g., deep brain stimulators, vagus nerve stimulators) in close proximity to the TMS coil

Relative contraindications — situations that require careful risk-benefit evaluation — include a personal or family history of epilepsy, a history of traumatic brain injury, current use of medications that lower the seizure threshold, and pregnancy (for which data are limited).

TMS is not associated with systemic side effects because the magnetic pulses act locally on brain tissue rather than circulating throughout the body. This is a meaningful distinction from pharmacological treatments and is one reason many patients prefer TMS.

TMS is offered at a growing number of psychiatric clinics, academic medical centers, and specialized neurostimulation practices across the United States and internationally. Choosing the right provider is important for both safety and treatment outcomes.

Key considerations when selecting a TMS provider:

• Clinical oversight: Treatment should be prescribed and supervised by a licensed psychiatrist or other qualified physician with training in TMS. While individual sessions are often administered by trained technicians, a physician should be involved in treatment planning, motor threshold determination, and ongoing clinical monitoring.
• Experience and volume: Providers who have treated a larger number of patients are generally better equipped to manage treatment parameters, troubleshoot side effects, and make clinical decisions about protocol adjustments. Ask how many patients the practice has treated and for how long they have been offering TMS.
• FDA-cleared equipment: Ensure the clinic uses FDA-cleared TMS devices from established manufacturers (e.g., NeuroStar, BrainsWay, MagVenture, Nexstim). Ask which device and protocol the clinic uses and why.
• Comprehensive evaluation: A reputable provider will conduct a thorough psychiatric evaluation before recommending TMS, rather than offering it as a first option without assessing your clinical history and treatment needs.
• Outcome tracking: Good clinics routinely administer standardized symptom rating scales (such as the PHQ-9 for depression) at regular intervals to monitor progress and make data-driven treatment decisions.

You can find TMS providers through several channels: your psychiatrist or primary care physician may offer referrals; manufacturer websites often have provider locators; academic medical centers with psychiatry departments frequently have TMS programs; and the Clinical TMS Society (cTMSs) maintains resources for patients seeking qualified providers.

Be cautious of clinics that make exaggerated claims about effectiveness, guarantee results, or offer TMS for conditions where evidence is minimal without transparent disclosure of the investigational nature of such use.

Cost and insurance coverage remain significant barriers to accessing TMS therapy for many individuals. Understanding the financial landscape is important for making informed treatment decisions.

Cost: A full course of TMS treatment (30–36 sessions) typically costs between $6,000 and $15,000 without insurance, depending on the geographic region, provider, device used, and protocol. Individual sessions generally range from $200 to $500 each. Accelerated protocols may have different pricing structures.

Insurance coverage: The insurance landscape for TMS has improved substantially since the treatment first became available. Most major commercial insurance carriers, including Aetna, Cigna, UnitedHealthcare, Anthem/Blue Cross Blue Shield, and others, now cover TMS for treatment-resistant depression, though coverage criteria vary. Common requirements include:

• A confirmed diagnosis of major depressive disorder
• Documentation of failed response to a specified number of antidepressant trials (often 2–4 medications from different classes, each at adequate dose and duration)
• Sometimes a requirement for a failed trial of psychotherapy
• Prior authorization approval before treatment begins

Medicare covers TMS for treatment-resistant depression in most states, though specific coverage determinations can vary by Medicare Administrative Contractor. Medicaid coverage varies significantly by state.

Coverage for TMS for OCD and other conditions is less consistent and may require additional advocacy or appeal. Some clinics have dedicated insurance coordinators who can help navigate the authorization process.

Accessibility challenges:

• Geographic availability: TMS is more widely available in urban and suburban areas. Rural communities often lack nearby providers, requiring significant travel for daily treatment over several weeks.
• Time commitment: Standard protocols require daily sessions five days a week for 6–9 weeks, which can be difficult for individuals with demanding work schedules, caregiving responsibilities, or limited transportation. Accelerated protocols like iTBS (shorter sessions) and the SAINT protocol (compressed over five days) may help address this barrier, though the SAINT protocol is not yet widely available outside research settings.
• Financial access: Even with insurance, copays and deductibles can be substantial. Some clinics offer payment plans or financing options.

TMS is one tool in a broader continuum of treatments for depression and other mental health conditions. It is important to consider the full range of options, either as alternatives or as complementary approaches used alongside TMS.

Psychotherapy: Evidence-based psychotherapies remain among the most effective treatments for depression and many other mental health conditions. Cognitive Behavioral Therapy (CBT) has the most robust evidence base for depression, with comparable efficacy to antidepressant medication for moderate depression. Other effective modalities include Behavioral Activation, Interpersonal Therapy (IPT), and Acceptance and Commitment Therapy (ACT). For OCD, Exposure and Response Prevention (ERP) is the gold-standard psychotherapy. Many individuals benefit from combining psychotherapy with TMS or other treatments.

Pharmacotherapy: Antidepressant medications — including SSRIs, SNRIs, atypical antidepressants, tricyclic antidepressants, and MAOIs — remain first-line treatments for moderate to severe depression. Augmentation strategies (adding a second medication, such as an atypical antipsychotic, lithium, or thyroid hormone) are well-established approaches for treatment-resistant depression. Esketamine (Spravato), an FDA-approved nasal spray derived from ketamine, is another option for treatment-resistant depression that works through a different mechanism (NMDA receptor modulation).

Electroconvulsive Therapy (ECT): ECT remains the most effective acute treatment for severe, treatment-resistant depression, with response rates of approximately 70–80% and remission rates of 50–60%. It is particularly appropriate for individuals with psychotic features, severe suicidality, or catatonia. The tradeoff is the need for general anesthesia and the risk of temporary cognitive side effects, particularly retrograde amnesia. ECT may be considered when TMS has not been effective or when the clinical situation requires a more rapid and robust response.

Other neuromodulation approaches:

• Vagus Nerve Stimulation (VNS): An implanted device that stimulates the vagus nerve. FDA-approved for treatment-resistant depression, but requires surgery and has a slow onset of action.
• Deep Brain Stimulation (DBS): An investigational neurosurgical approach for the most treatment-refractory cases. Reserved for research settings.
• Transcranial Direct Current Stimulation (tDCS): A less powerful form of non-invasive brain stimulation using low-level electrical currents. Research shows modest effects for depression, but it is not FDA-cleared for psychiatric indications in the United States.

Lifestyle and complementary approaches: Regular aerobic exercise has a well-established evidence base as an adjunctive treatment for depression. Adequate sleep hygiene, structured daily routines, social engagement, and stress management practices can support recovery. Mindfulness-based cognitive therapy (MBCT) has evidence for preventing depressive relapse. These approaches work best as supplements to, rather than replacements for, primary treatments in moderate to severe depression.

If you are living with depression or another mental health condition and have not experienced adequate improvement with initial treatments, TMS is worth discussing with your mental health provider. It is particularly relevant if:

• You have tried two or more antidepressant medications at adequate doses for adequate durations without sufficient relief
• You experience intolerable side effects from medications that limit your ability to continue pharmacotherapy
• You are looking for a non-medication treatment approach to add to or replace your current regimen
• You have been diagnosed with OCD and have not responded adequately to standard treatments

The decision to pursue TMS should be made collaboratively with a qualified psychiatrist or mental health professional who can assess your individual clinical situation, review your treatment history, and help determine whether TMS is appropriate for your specific needs.

If you are in crisis or experiencing thoughts of self-harm or suicide, TMS is not an emergency intervention. Contact the 988 Suicide and Crisis Lifeline (call or text 988), go to your nearest emergency room, or call 911. TMS is a planned treatment for ongoing conditions, not an acute crisis intervention.

Ultimately, TMS represents a meaningful advance in the treatment of depression and other mental health conditions — offering a safe, well-tolerated, and effective option for individuals who have not found relief through other means. As research continues, access expands, and protocols become more efficient, TMS is likely to play an increasingly central role in comprehensive mental health care.